Evidence map›Paper›PMID 41640440›Full record

ReviewFrontiers in oncology2025

Transforming cervical cancer pathological diagnosis through artificial intelligence: progress, performance, and barriers to clinical implementation.

Yue Zhang, Jiangbo Yuan, Lin Chen

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yue ZhangShaanxi Provincial People's Hospital, Xi'an, China.
Jiangbo YuanPucheng County Hospital, Weinan, China.
Lin ChenShaanxi Provincial People's Hospital, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Cervical cancer faces significant pathological diagnosis challenges including pathologist shortages, subjective interpretation, and inconsistent detection rates. This systematic review evaluates AI technology's application status, development level, and key challenges in cervical cancer pathological diagnosis. Methods: A systematic literature review across three databases (PubMed/MEDLINE, Scopus, Web of Science) covering January 2015 to August 2025. Search terms included "artificial intelligence," "cervical cancer," "pathological diagnosis," "histopathology," "machine learning," and "deep learning." Studies involving AI applications in cervical cancer pathological diagnosis were included, encompassing histopathological, immunohistochemical, and molecular pathological diagnoses. Animal studies, cytological screening, and genomic analyses unrelated to pathological diagnosis were excluded. Results: From 1,847 identified articles, 56 studies were included. AI technology demonstrated substantial potential in histopathological image analysis, diagnostic support systems, and accuracy validation. Deep learning architectures, particularly convolutional neural networks, achieved 92-98% diagnostic accuracy while reducing processing time from 8-15 minutes to 1-3 minutes per case. However, significant implementation challenges persist including standardization issues, limited clinical validation, and substantial infrastructure costs. Conclusion: AI technology shows broad application prospects in cervical cancer pathological diagnosis, potentially alleviating pathologist shortages and improving diagnostic standardization. The technology particularly suits cervical cancer prevention in resource-limited regions, supporting global elimination goals, though standardization and validation challenges require addressing before widespread clinical implementation.

Indexed as

artificial intelligencecervical cancerdeep learningdigital pathologymachine learningpathological diagnosis

Identifiers

PMID41640440
PMCPMC12864132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.